Why Eisai’s Fycompa oral suspension quietly stands out for families

Eisai’s Fycompa 0.5 mg/ml oral suspension targets a very concrete everyday problem in epilepsy care - getting precise doses into children and adults who struggle with tablets. What the liquid form delivers, where it demands care, and why Eisai is betting on it.

Reviewed: ad hoc news Accessory & Components desk. Edited and checked on 2026-06-17, 12:59. Details in the imprint.

Fycompa 0.5 mg/ml oral suspension is one of those Eisai products that only reveal their importance when you watch a caregiver draw up a dose at 6 a.m. for a teenager who cannot swallow tablets. The thick, almost syrupy liquid, the click of the bottle adapter, the numbered syringe - it all aims at one promise: the right amount of antiepileptic drug, without a fight over pills.

What Fycompa suspension offers

Fycompa (perampanel) is an antiepileptic drug that targets a specific glutamate receptor subtype, the AMPA receptor, and is used to treat partial-onset seizures with or without secondary generalization, as well as primary generalized tonic-clonic seizures in certain patients. According to the official European product information, the 0.5 mg/ml oral suspension is indicated from 4 years of age for partial-onset seizures and from 7 years of age for primary generalized tonic-clonic seizures when used as adjunctive therapy. The EMA summary for Fycompa describes the approved indications and age ranges in detail.

Where the suspension sets itself apart from the tablet is not its active ingredient but its form. A white to off-white, thixotropic liquid, it is designed to be shaken into a homogenous state and then drawn up with a dosing syringe that clicks into a bottle adapter, to minimize spillage and dose errors for patients who cannot or should not swallow solid tablets.

Dosing, handling, everyday use

The dosing concept of Fycompa suspension mirrors the tablet but in a more flexible way: each millilitre contains 0.5 mg perampanel, allowing physicians and caregivers to titrate in 0.5 mg steps, rather than the 2 mg jumps of the tablet strength. The official prescribing information stresses slow weekly titration, typically starting at 2 mg once daily and increasing based on seizure control and tolerability. Eisai’s professional dosing guidance for Fycompa outlines these titration schemes.

In practice, that means caregivers shake the bottle vigorously for at least 30 seconds, fit the syringe into the adapter, invert the bottle and draw up the precise millilitre mark prescribed. The liquid has a sweet, slightly artificial taste profile to mask bitterness, but families still often chill the bottle or chase it with juice to make the routine more acceptable for younger children.

Safety profile and warnings

Perampanel’s safety profile in the suspension is essentially the same as with the tablet, and it is not a mild drug. Dizziness, somnolence, headache, irritability and falls are among the most frequently reported adverse reactions, and the labeling carries a clear warning for serious psychiatric and behavioral reactions such as aggression, hostility and, rarely, homicidal ideation. The US prescribing information for Fycompa devotes several pages to these neuropsychiatric risks.

For day-to-day life this means that families and clinicians must watch for subtle changes in mood and behavior, especially during dose increases. Patients are also advised not to drive or operate machinery until they know how Fycompa affects them, and the once-daily evening dosing is a nod to these central nervous system effects, bundling drowsiness away from daytime activities where possible.

Where the liquid form shines

From a purely clinical point of view, perampanel is the same molecule whether swallowed as a tablet or taken as suspension, but for certain patients the liquid turns a theoretical option into a practical one. Children with developmental delay, adults after stroke, and people with swallowing disorders often simply cannot manage large tablets consistently, and crushed tablets are not an option for Fycompa because of dose uniformity and the risk of aerosolized powder.

Here the bottle, adapter and syringe setup looks almost trivial but becomes decisive. The clear graduations, the click when the adapter seats, the routine of shake-measure-administer give structure to a therapy where missing one or two doses can noticeably destabilize seizure control. Caregivers report that the routine, once learned, integrates into morning and evening rituals more smoothly than fighting over a bitter pill.

Limitations and everyday annoyances

The suspension is not without drawbacks. Once opened, the bottle comes with a limited shelf life, typically a few months, after which any remaining liquid must be discarded even if the family has carefully stored it below 30 degrees Celsius and kept it tightly closed. For some households, especially those on lower doses, this means throwing away a visible amount of expensive medication.

Travel also needs more planning. A glass bottle that must be shaken and kept upright takes more space in a bag than a blister strip of tablets, and airport security staff sometimes scrutinize the viscous white liquid more closely. Families often decant into a smaller bottle with a pharmacy label or carry the original packaging and prescription to avoid awkward discussions at checkpoints.

Market position and availability

Fycompa is a global brand for Eisai, with the oral suspension available in markets such as the European Union, the United States and Japan, usually via specialist prescription and often under reimbursement schemes for chronic epilepsy. In many countries it is positioned as an adjunctive therapy after first-line agents such as levetiracetam or valproate have failed to control seizures, rather than as the first drug a newly diagnosed patient receives.

Pricing varies widely by market and payer system, but as a branded antiepileptic Fycompa typically sits near the upper end of reimbursed antiseizure medications, a position that Eisai seeks to justify with its once-daily dosing, targeted mechanism and the option of a child-friendly liquid. In Germany and other European markets, hospital formularies and neurological societies’ guidelines play a central role in whether the suspension is routinely stocked on wards or reserved for specific patient groups.

Eisai’s strategy and stock context

Eisai has made neurology, including epilepsy, one of its strategic pillars alongside oncology and Alzheimer’s disease, and Fycompa is part of what management calls its “value creation” portfolio of established products. Recent announcements about expanding manufacturing capacity in Hatfield in the United Kingdom underline that the company expects continued demand for its neurology range, even as patent cliffs loom for some brands and as Eisai invests heavily in biologics and antibody therapies for dementia and cancer.

Shares of Eisai Co Ltd (JP3160400002) trade in Tokyo on the TSE Prime Market under the code 4523, with the company presenting itself as a mid-sized global pharmaceutical player balancing high-risk research projects with steady sales from products like Fycompa suspension and its other central nervous system therapies.

Key facts on Fycompa oral suspension

• Product: Fycompa 0.5 mg/ml oral suspension (perampanel)
• Manufacturer: Eisai Co., Ltd.
• Category: Accessory/Spare part - alternative formulation of established epilepsy drug
• Launch: Gradual roll-out since mid-2010s, depending on market
• RRP / Price: Varies by country and pack size, positioned as a branded antiepileptic at the upper end of reimbursed ranges
• Availability: Prescription-only in neurology and pediatrics, distributed through hospital pharmacies and specialist retail in markets including EU, US and Japan
• Target group: Children and adults with partial-onset or primary generalized tonic-clonic seizures who need flexible dosing or cannot swallow tablets
• Highlight / USP: Liquid, once-daily AMPA receptor antagonist formulation enabling precise titration and easier administration for patients with swallowing difficulties

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.